vs
泛林半导体（LRCX）与美敦力（MDT）财务数据对比。点击上方公司名可切换其他公司
美敦力的季度营收约是泛林半导体的1.7倍（$9.0B vs $5.3B），泛林半导体净利率更高（29.8% vs 15.3%，领先14.5%），泛林半导体同比增速更快（22.1% vs 6.6%），泛林半导体自由现金流更多（$1.2B vs $457.0M），过去两年泛林半导体的营收复合增速更高（18.7% vs 5.3%）
泛林半导体是美国面向半导体行业的晶圆制造设备及相关服务供应商，产品主要用于前道晶圆加工，生产半导体器件的有源组件与互连线路，同时也推出后道晶圆级封装、微机电系统（MEMS）等领域的相关制造设备。
美敦力是全球知名的医疗设备企业，法定及行政总部位于爱尔兰，运营总部设在美国明尼苏达州明尼阿波利斯。2015年集团收购爱尔兰企业柯惠后将注册地迁至爱尔兰，目前业务覆盖超150个国家，员工逾9万名，专注于研发生产各类医疗技术产品及治疗解决方案。
LRCX vs MDT — 直观对比
营收规模更大
MDT
是对方的1.7倍
$5.3B
营收增速更快
LRCX
高出15.5%
6.6%
净利率更高
LRCX
高出14.5%
15.3%
自由现金流更多
LRCX
多$762.2M
$457.0M
两年增速更快
LRCX
近两年复合增速
5.3%
损益表 — Q2 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $9.0B |
| 净利润 | $1.6B | $1.4B |
| 毛利率 | 49.6% | 65.8% |
| 营业利润率 | 33.9% | 18.8% |
| 净利率 | 29.8% | 15.3% |
| 营收同比 | 22.1% | 6.6% |
| 净利润同比 | 33.8% | 8.2% |
| 每股收益（稀释后） | $1.26 | $1.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LRCXMDT
| Q4 25 | $5.3B | $9.0B | ||
| Q3 25 | $5.3B | $8.6B | ||
| Q2 25 | $5.2B | $8.9B | ||
| Q1 25 | $4.7B | $8.3B | ||
| Q4 24 | $4.4B | $8.4B | ||
| Q3 24 | $4.2B | $7.9B | ||
| Q2 24 | $3.9B | $8.6B | ||
| Q1 24 | $3.8B | $8.1B |
净利润LRCXMDT
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.6B | $1.0B | ||
| Q2 25 | $1.7B | $1.1B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.2B | $1.3B | ||
| Q3 24 | $1.1B | $1.0B | ||
| Q2 24 | $1.0B | $654.0M | ||
| Q1 24 | $965.8M | $1.3B |
毛利率LRCXMDT
| Q4 25 | 49.6% | 65.8% | ||
| Q3 25 | 50.4% | 65.0% | ||
| Q2 25 | 50.1% | 64.8% | ||
| Q1 25 | 49.0% | 66.5% | ||
| Q4 24 | 47.4% | 64.9% | ||
| Q3 24 | 48.0% | 65.1% | ||
| Q2 24 | 47.5% | 64.5% | ||
| Q1 24 | 47.5% | 65.6% |
营业利润率LRCXMDT
| Q4 25 | 33.9% | 18.8% | ||
| Q3 25 | 34.4% | 16.8% | ||
| Q2 25 | 33.7% | 16.1% | ||
| Q1 25 | 33.1% | 19.9% | ||
| Q4 24 | 30.5% | 19.0% | ||
| Q3 24 | 30.3% | 16.1% | ||
| Q2 24 | 29.1% | 12.3% | ||
| Q1 24 | 27.9% | 18.3% |
净利率LRCXMDT
| Q4 25 | 29.8% | 15.3% | ||
| Q3 25 | 29.5% | 12.1% | ||
| Q2 25 | 33.3% | 11.8% | ||
| Q1 25 | 28.2% | 15.6% | ||
| Q4 24 | 27.2% | 15.1% | ||
| Q3 24 | 26.8% | 13.2% | ||
| Q2 24 | 26.4% | 7.6% | ||
| Q1 24 | 25.5% | 16.3% |
每股收益（稀释后）LRCXMDT
| Q4 25 | $1.26 | $1.07 | ||
| Q3 25 | $1.24 | $0.81 | ||
| Q2 25 | $1.34 | $0.81 | ||
| Q1 25 | $1.03 | $1.01 | ||
| Q4 24 | $0.92 | $0.99 | ||
| Q3 24 | $0.86 | $0.80 | ||
| Q2 24 | $7.78 | $0.50 | ||
| Q1 24 | $7.34 | $0.99 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.2B | $8.3B |
| 总债务越低越好 | $3.7B | $27.7B |
| 股东权益账面价值 | $10.1B | $48.7B |
| 总资产 | $21.4B | $91.3B |
| 负债/权益比越低杠杆越低 | 0.37× | 0.57× |
8季度趋势，按日历期对齐
现金及短期投资LRCXMDT
| Q4 25 | $6.2B | $8.3B | ||
| Q3 25 | $6.7B | $8.1B | ||
| Q2 25 | $6.4B | $9.0B | ||
| Q1 25 | $5.5B | $7.9B | ||
| Q4 24 | $5.7B | $8.0B | ||
| Q3 24 | $6.1B | $7.8B | ||
| Q2 24 | $5.8B | $8.0B | ||
| Q1 24 | $5.7B | $8.3B |
总债务LRCXMDT
| Q4 25 | $3.7B | $27.7B | ||
| Q3 25 | $3.7B | $26.2B | ||
| Q2 25 | $3.7B | $25.6B | ||
| Q1 25 | $3.7B | $24.0B | ||
| Q4 24 | $4.5B | $24.6B | ||
| Q3 24 | $4.5B | $26.3B | ||
| Q2 24 | $4.5B | $23.9B | ||
| Q1 24 | $4.5B | $24.2B |
股东权益LRCXMDT
| Q4 25 | $10.1B | $48.7B | ||
| Q3 25 | $10.2B | $47.9B | ||
| Q2 25 | $9.9B | $48.0B | ||
| Q1 25 | $9.5B | $49.4B | ||
| Q4 24 | $8.8B | $48.5B | ||
| Q3 24 | $8.5B | $47.9B | ||
| Q2 24 | $8.5B | $50.2B | ||
| Q1 24 | $8.0B | $51.8B |
总资产LRCXMDT
| Q4 25 | $21.4B | $91.3B | ||
| Q3 25 | $21.9B | $91.0B | ||
| Q2 25 | $21.3B | $91.7B | ||
| Q1 25 | $20.0B | $90.0B | ||
| Q4 24 | $19.8B | $90.0B | ||
| Q3 24 | $19.5B | $89.7B | ||
| Q2 24 | $18.7B | $90.0B | ||
| Q1 24 | $18.3B | $90.8B |
负债/权益比LRCXMDT
| Q4 25 | 0.37× | 0.57× | ||
| Q3 25 | 0.37× | 0.55× | ||
| Q2 25 | 0.38× | 0.53× | ||
| Q1 25 | 0.39× | 0.49× | ||
| Q4 24 | 0.51× | 0.51× | ||
| Q3 24 | 0.53× | 0.55× | ||
| Q2 24 | 0.52× | 0.48× | ||
| Q1 24 | 0.56× | 0.47× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.5B | $925.0M |
| 自由现金流经营现金流 - 资本支出 | $1.2B | $457.0M |
| 自由现金流率自由现金流/营收 | 22.8% | 5.1% |
| 资本支出强度资本支出/营收 | 4.9% | 5.2% |
| 现金转化率经营现金流/净利润 | 0.93× | 0.67× |
| 过去12个月自由现金流最近4个季度 | $6.2B | $5.2B |
8季度趋势，按日历期对齐
经营现金流LRCXMDT
| Q4 25 | $1.5B | $925.0M | ||
| Q3 25 | $1.8B | $1.1B | ||
| Q2 25 | $2.6B | $2.5B | ||
| Q1 25 | $1.3B | $2.6B | ||
| Q4 24 | $741.9M | $958.0M | ||
| Q3 24 | $1.6B | $986.0M | ||
| Q2 24 | $862.4M | $2.8B | ||
| Q1 24 | $1.4B | $2.5B |
自由现金流LRCXMDT
| Q4 25 | $1.2B | $457.0M | ||
| Q3 25 | $1.6B | $584.0M | ||
| Q2 25 | $2.4B | $2.1B | ||
| Q1 25 | $1.0B | $2.1B | ||
| Q4 24 | $553.6M | $554.0M | ||
| Q3 24 | $1.5B | $466.0M | ||
| Q2 24 | $761.7M | $2.4B | ||
| Q1 24 | $1.3B | $2.1B |
自由现金流率LRCXMDT
| Q4 25 | 22.8% | 5.1% | ||
| Q3 25 | 29.9% | 6.8% | ||
| Q2 25 | 46.1% | 23.2% | ||
| Q1 25 | 21.6% | 25.3% | ||
| Q4 24 | 12.7% | 6.6% | ||
| Q3 24 | 35.0% | 5.9% | ||
| Q2 24 | 19.7% | 27.4% | ||
| Q1 24 | 33.8% | 26.3% |
资本支出强度LRCXMDT
| Q4 25 | 4.9% | 5.2% | ||
| Q3 25 | 3.5% | 5.9% | ||
| Q2 25 | 3.3% | 5.1% | ||
| Q1 25 | 6.1% | 5.7% | ||
| Q4 24 | 4.3% | 4.8% | ||
| Q3 24 | 2.7% | 6.6% | ||
| Q2 24 | 2.6% | 5.0% | ||
| Q1 24 | 2.7% | 4.3% |
现金转化率LRCXMDT
| Q4 25 | 0.93× | 0.67× | ||
| Q3 25 | 1.13× | 1.05× | ||
| Q2 25 | 1.48× | 2.39× | ||
| Q1 25 | 0.98× | 1.99× | ||
| Q4 24 | 0.62× | 0.75× | ||
| Q3 24 | 1.40× | 0.95× | ||
| Q2 24 | 0.85× | 4.25× | ||
| Q1 24 | 1.43× | 1.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LRCX
| System | $3.4B | 63% |
| Customer Supportand Other | $2.0B | 37% |
MDT
| Cardiac Rhythm And Heart Failure Division | $1.8B | 20% |
| Surgical Endoscopy | $1.7B | 19% |
| Other | $1.3B | 14% |
| Structural Heart And Aortic Division | $956.0M | 11% |
| Diabetes Group | $757.0M | 8% |
| Specialty Therapies Division | $744.0M | 8% |
| Coronary And Peripheral Vascular Division | $655.0M | 7% |
| Neuromodulation Division | $520.0M | 6% |
| Acute Care Monitoring | $493.0M | 6% |
| IE | $35.0M | 0% |
